Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorGarcía García de Paredes, Ana-
dc.contributor.authorManicardi, Nicolo-
dc.contributor.authorTellez, Luis-
dc.contributor.authorIbañez, Luis-
dc.contributor.authorRoyo, Félix-
dc.contributor.authorBermejo, Javier-
dc.contributor.authorBlanco, Carolina-
dc.contributor.authorFondevila Campo, Constantino-
dc.contributor.authorFernández Lanza, Val-
dc.contributor.authorGarcía Bermejo, Laura-
dc.contributor.authorFalcón Pérez, Juan Manuel-
dc.contributor.authorBañares, Rafael-
dc.contributor.authorGracia Sancho, Jordi-
dc.contributor.authorAlbillos, Agustín-
dc.description.abstractNoninvasive staging of decompensated cirrhosis is an unmet clinical need. The aims of this study were to characterize and validate a novel microRNA (miRNA) signature to stage decompensated cirrhosis and predict the portal pressure and systolic cardiac response to nonselective beta-blockers (NSBBs). Serum samples from patients with decompensated cirrhosis (n = 36) and healthy controls (n = 36) were tested for a novel signature of five miRNAs (miR-452-5p, miR-429, miR-885-5p, miR-181b-5p, and miR-122-5p) identified in the secretome of primary human hepatocytes and for three miRNAs (miR-192-5p, miR-34a-5p, and miR-29a-5p) previously discovered as biomarkers of chronic liver disease. All patients had ascites, which was refractory in 18 (50%), and were placed on NSBBs for variceal bleeding prophylaxis. In all patients, serum miRNAs, hepatic venous pressure gradient, and an echocardiogram study were performed before and 1 month after NSBBs. Patients with cirrhosis had lower serum levels of miR-429, miR-885-5p, miR-181b-5p, miR-122-5p, miR-192-5p, and miR-29a-5p (P < 0.05). Baseline serum miR-452-5p and miR-429 levels were lower in NSBB responders (P = 0.006). miR-181b-5p levels were greater in refractory ascites than in diuretic-sensitive ascites (P = 0.008) and correlated with serum creatinine. miR-452-5p and miR-885-5p were inversely correlated with baseline systemic vascular resistance (ρ = −0.46, P = 0.007; and ρ = −0.41, P = 0.01, respectively) and with diminished systolic contractility (ρ = −0.55, P = 0.02; and ρ = −0.55, P = 0.02, respectively) in patients with refractory ascites after NSBBs. Conclusion: Analysis of a miRNA signature in serum discriminates between patients with decompensated cirrhosis who show more severe systemic circulatory dysfunction and compromised systolic function after beta-blockade and those more likely to benefit from NSBBs.-
dc.format.extent14 p.-
dc.publisherJohn Wiley & Sons-
dc.relation.isformatofReproducció del document publicat a:
dc.relation.ispartofHepatology Communications, 2020, vol. 5, num. 2, p. 309-322-
dc.rightscc-by (c) García García de Paredes, Ana et al., 2020-
dc.subject.classificationCirrosi hepàtica-
dc.subject.classificationMicro RNAs-
dc.subject.classificationMarcadors bioquímics-
dc.subject.otherHepatic cirrhosis-
dc.subject.otherBiochemical markers-
dc.titleMolecular Profiling of Decompensated Cirrhosis by a Novel MicroRNA Signature-
Appears in Collections:Articles publicats en revistes (Cirurgia i Especialitats Medicoquirúrgiques)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Files in This Item:
File Description SizeFormat 
705487.pdf969.85 kBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons